Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

A at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.

Interim 12-Week Safety Analysis of PROVE 1

In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.

In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. Vertex is conducting a global Phase 2b clinical development program for telaprevir consis
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:11/21/2014)... SAN CLEMENTE, Calif. , Nov. 21, 2014 /PRNewswire/ ... Lab Coats and Performance Scrubs carried out a new ... the medical industry,s very first "limited edition" lab ... the first female professors of surgery in the world. ... departure from its unisex predecessors, with a sleek envelope ...
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
Breaking Medicine Technology:Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... DALLAS, Nov. 1 Death resulting from,influenza, often referred ... heart disease than among patients with any other chronic ... heart disease,patients conducted by Harris Interactive on behalf of ... with the American Heart,Association (AHA), more than one in ...
... The U.S. Department of,Health and Human Services (HHS), ... of Health of the United Mexican States today ... surveillance,prevention, and control of infectious diseases for the ... of their peoples. The Memorandum of Understanding ...
Cached Medicine Technology:Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 2Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 3Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 4United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies 2
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has ... new products are available at low rates up to ... of the new emergency doors. The emergency door adopts ... choose from several colors. All of the products are ... release is not as easy as many people think. ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its ... beach wedding dresses. “If you are looking for gorgeous ... soon as possible. Here you can enjoy 70% off ... , Holding a big marriage ceremony is the most ... beach wedding dress is uppermost priority. Ophelia, one of ...
(Date:11/23/2014)... November 23, 2014 Wright & Schulte ... of Ohio and West Virginia residents who allege that ... health disorders due to drinking C8 contaminated water ... West Virginia. According to the C8 complaints, the plaintiffs ... worked or lived in at least one of the ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Cancer researchers ... a connection between intercellular communication tunnels and the growth ... the full story on the Surviving Mesothelioma website. ... and the University of Minnesota have just released their ... information and materials between cells. They found that ...
(Date:11/22/2014)... 2014 BambooFlooringChina.com is a famous ... proudly released its new collection of bamboo mats ; ... to 29% off. , According to the sales ... grass, making it a highly renewable resource. Their bamboo mats ... mixing color which comes from natural bamboo with caramel bamboo ...
Breaking Medicine News(10 mins):Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2
... One in eight parents reported that his or ... laboratory testing and/or appointments with specialists during the ... payment, according to a study, presented Sunday, Oct. 3, ... and Exhibition in San Francisco. For the ...
... , FRIDAY, Oct. 1 (HealthDay News) -- Doctors who take ... lifestyle habits to their patients than doctors who gobble down ... hit the gym, according to new research. Additionally, the ... they,d been well-trained to counsel their patients on lifestyle changes ...
... identify obscure cartoon characters than the native plants and animals ... connection to the natural world can have a profound impact ... author who coined the phrase, "nature-deficit disorder," will address this ... Pediatrics (AAP) National Conference & Exhibition Saturday, Oct. 2. His ...
... department at a mid-sized hospital were able to increase ... for measuring general technologist productivity, according to a study ... American College of Radiology ( www.jacr.org ). ... priorities that may be difficult to achieve simultaneously," said ...
... Johns Hopkins scientists have discovered a way to turn off ... mice, a discovery that could have implications for the millions ... peanuts and milk. The findings, published online in the ... could be trained to tolerate food allergies that lead to ...
... review article published in the October issue of ... Clinic physicians differentiate the ethical and legal permissibility ... comfort measures, specifically palliative sedation, from that of ... that palliative sedation has an important place on ...
Cached Medicine News:Health News:1 in 8 parents forgoes pediatrician-recommended care 2Health News:Doctors' Health, Well-Being Affect Patient Counseling 2Health News:Doctors' Health, Well-Being Affect Patient Counseling 3Health News:Johns Hopkins researchers turn off severe food allergies in mice 2
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... Sir John Charnley and CMW, Inc. ... develop bone cements exclusively for orthopaedic ... 40 years of performance and excellence ... offers one of the first proven ...
... Blood Flow Analyzer is a fast, clinically ... diagnosis of low and normal-tension glaucoma., ,The ... fast, clinically proven measurement that improves detection ... the management of glaucoma, and detection of ...
Occu-Flo Plugs Offer: , Easy Insertion , A polished, smooth, transparent finish which creates immediate patient comfort and adaptation , High tolerance by patients , No discomfort should removal be ...
Medicine Products: